<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40084">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01753323</url>
  </required_header>
  <id_info>
    <org_study_id>CKAF156X2201</org_study_id>
    <nct_id>NCT01753323</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection</brief_title>
  <official_title>A Proof-of-concept, Open Label Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Thailand: Institute for Development of Human Research Protection (IHRP)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria
      patients with P. vivax or P. falciparum infection after 3 day dosing with KAF156 at 400
      mg/day (Part 1) and single dosing with KAF156 at 800mg (Part 2)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Parasite clearance time</measure>
    <time_frame>baseline and up to 5 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in calculated parasite count in blood, using thin film, thick film and blood density assessments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>28-day cure rate</measure>
    <time_frame>day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent of patients with blood parasite count of zero after 28 days of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECG monitoring</measure>
    <time_frame>Days 1, 2, 3 and 5</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ECGs will be monitored at 3 hours post dose on day 1; pre-dose, and 3 hours post dose on Day 2; pre-dose, 3, 5, 24, 48 hours post dose on Day 3 and at study completion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) 0-24h</measure>
    <time_frame>Days 1 and 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in AUC 0-24h will be analyzed using parent drug in plasma samples. On Day 1: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Racc) (=AUC0-24h, day3/AUC0-24h, day1)</measure>
    <time_frame>Day s 1 and 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in accumulation ratio will be analyzed using parent drug in plasma samples. On Day 1: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>Days 1 and 3 (Part 1); Day 1 (Part 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in Cmax will be analyzed using parent drug in plasma samples. On Day 1 of Part 1: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3 of Part 1 and Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax)</measure>
    <time_frame>Days 1 and 3 of (Part 1); Day 1 (Part 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Tmax will be analyzed using parent drug in plasma samples. On Day 1 of Part 1: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3 of Part 1 and Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2)</measure>
    <time_frame>Day 3 (Part 1); Day 1 (Part 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in half life will be analyzed using parent drug in plasma samples. On Day 3 of Part 1 and Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL/F )</measure>
    <time_frame>Day 3 (Part 1); Day 1 (Part 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes inCL/F will be analyzed using parent drug in plasma samples . On Day 3 of Part 1 and Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal elimination phase following extravascular administrationi(Vz/F)</measure>
    <time_frame>Day 3 of Part 1; Day 1 of Part 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in apparent volume of distribution will be analyzed using parent drug in plasma samples. On Day 3 of Part 1 and Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) last</measure>
    <time_frame>Day 3 (Part 1); Day 1 (Part 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in AUC -last will be analyzed using parent drug in plasma samples. On Day 3 of Part 1 and Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) 0-t</measure>
    <time_frame>Day 1 (Part 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in AUC 0-t will be analyzed using parent drug in plasma samples On Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) inf</measure>
    <time_frame>Day 1 (Part 2)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in AUC inf will be analyzed using parent drug in plasma samples. On Day 1 of Part 2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab evaluation - hematology</measure>
    <time_frame>Days 2, 3, 5, study completion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Changes in hematology will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab evaluation - blood chemistry</measure>
    <time_frame>Day 2, 3, 5, study completion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Changes in blood chemistry will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab evaluation - urinalysis</measure>
    <time_frame>Day 2, 3, 5, study completion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Changes in urinalysis will be measured</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 10 subjects with Plasmodium vivax malaria will receive KAF156 400 mg once a day for three days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 10 subjects with Plasmodium falciparum malaria will receive KAF156 400mg once a day for three days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 20 subjects with Plasmodium falciparum malaria will receive single dose of KAF156 800mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAF156 400 mg</intervention_name>
    <description>KAF156 will be supplied as tablets for oral use.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAF156 800 mg</intervention_name>
    <description>KAF156 will be supplied as tablets for oral use.</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Male and female patients aged 20 to 60 years;Presence of mono-infection of P. falciparum
        or P. vivax; Weight between 40 kg to 90 kg.

        Exclusion Criteria:

          -  Patients with signs and symptoms of severe/complicated malaria

          -  Infection with more than one parasite species

          -  Women of child-bearing potential; pregnant or nursing women

          -  Those who have taken any anti-malarial treatment in the preceding 14 days or other
             investigational drugs within 30 days or 5 half-lives
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ratchabari</city>
        <zip>70180</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Srisaket</city>
        <zip>33140</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Srisaket</city>
        <zip>33150</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tak</city>
        <zip>63110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tak</city>
        <zip>63110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tak</city>
        <zip>63140</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hanoi</city>
        <zip>10000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>December 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute malaria, KAF156</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Vivax</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
